Floatz logo

48 assets in Neuroendocrine Carcinoma

Therapeutic assets addressing Neuroendocrine Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Etoposide
Neuroendocrine Carcinoma
National Cancer Institute (NCI)P2B (63)
Cis-Diamminedichloroplatinum Ii
Neuroendocrine Carcinoma
National Cancer Institute (NCI)P2B (60)
Lurbinectedin
Neuroendocrine Carcinoma
Jazz PharmaceuticalsP2B (60)
Pembrolizumab
Neuroendocrine Carcinoma
Ochsner Health SystemP2B (60)
Tarlatamab
Neuroendocrine Carcinoma
National Cancer Institute (NCI)P2B (60)
Ipilimumab
Neuroendocrine Carcinoma
National Cancer Institute (NCI)P2B (59)
Carboplatin
Neuroendocrine Carcinoma
Phanes TherapeuticsP2B (58)
Nivolumab
Neuroendocrine Carcinoma
National Cancer Institute (NCI)P2B (58)
Immunoglobulin Half-Ig G1-Kappa/Scfv-H-Ch2-Ch3, Anti-(Homo Sapiens Ctla4 (Cytotoxic T-Lymphocyte-Associated Protein 4, Cd152)) And Anti-(Homo Sapienspdcd1 (Programmed Cell Death 1, Pd-1, Pd1, Cd279)), Monoclonal Antibody, Bispecific
Neuroendocrine Carcinoma
M.D. Anderson Cancer CenterP2B (57)
Nogitecan
Neuroendocrine Carcinoma
National Cancer Institute (NCI)P1/2B (57)
Belinostat
Neuroendocrine Carcinoma
National Cancer Institute (NCI)P2B (56)
Atezolizumab
Neuroendocrine Carcinoma
Phanes TherapeuticsP2CCC (54)
Oxodotreotide
Neuroendocrine Carcinoma
National Cancer Institute (NCI)P1/2CCC (54)
Cabozantinib
Neuroendocrine Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Capecitabine
Neuroendocrine Carcinoma
ECOG-ACRIN Cancer Research GroupP2CCC (53)
Dostarlimab
Neuroendocrine Carcinoma
UNICANCERP2CCC (53)
Fludeoxyglucose
Neuroendocrine Carcinoma
Rigshospitalet, DenmarkP2CCC (53)
Foslinanib
Neuroendocrine Carcinoma
TaiRx, Inc.P2CCC (53)
Iadademstat
Neuroendocrine Carcinoma
Fox Chase Cancer CenterP2CCC (53)
Ivocizumab
Neuroendocrine Carcinoma
Fudan UniversityP2CCC (53)
L-Kappa-H-Gamma1 (Knob) Chain Anti-Dll3 (1-705) [L-Kappa Anti-Dll3 (1-214) [V-Kappa (Homo Sapiens Igkv1-17*03 (94.9%) -Igkj2*01 (100%), Cdr-Imgt [6.3.9] (27-32.50-52.89-97)) (1-107) -Homo Sapiens Igkc*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')] -38-Mer (Ggggse Gkssgsgses Kstegkssgs Gseskstggggs) Linker (215-252) -H-Gamma-1 Heavy Chain Anti-Dll3 (253-705) [Vh (Homo Sapiens Ighv1-46*01 (92.9%) -(Ighd) -Ighj6*01 (94.7%), Cdr-Imgt [8.8.17] (278-285.303-310.349-365)) (253-376)-Homo Sapiens Ighg1*03, G1M3, Ng1M1, Ch1 R120, Ch3 E12, M14, G1V14 Ch2 A1.3, A1.2, G1V32 Ch3 W22 (Knob) (Ch1 R120 (473) (377-474), Hinge 1-15 (475-489), Ch2 L1.3>A (493), L1.2>A (494) (490-599), Ch3 E12 (615), M14 (617), T22>W (625) (600-704), Chs K2>Del (705)) (377-705)]]; L-Lambda6-H-Gamma1 (Hole) Chain Anti-Cd3E (1-707) [L-Lambda6 Anti-Cd3 (1'-215') [V-Lambda Musmus/Homsap (Mus Musculus Iglv1*01 (82.3%) -Iglj1*01 (100%)/Homo Sapiens Iglv7-46*01 (76.8%) -Iglj3*02 (100%), Cdr-Imgt [9.3.9] (26'-34'.52'-54'.91'-99')) (1'-109') -Homo Sapiens Iglc6*01 (100%) (110'-215')] -38-Mer (Ggggse Gkssgsgses Kstegkssgsgseskstggggs) Linker (216'-253') -H-Gamma-1 Anti-Cd3E (254'-707') [Vh Musmus/Homsap (Mus Musculus Ighv10-1*02 (92.9%) -(Ighd) -Ighj3*01 (100%)/Homo Sapiens Ighv3-73*01 (87.0%) -(Ighd) -Ighj6*01 (81.8%) T123>L (373'), S128>A (378'), Cdr-Imgt [8.10.16] (279'-286'.304'-313'.352'-367')) (254'-378')-Homo Sapiens Ighg1*03, G1M3, Ng1M1, Ch1 R120, Ch3 E12, M14, G1V14 Ch2 A1.3, A1.2, G1V33 Ch3 S22, A24, V86 (Hole), G1V83 Ch3 R115, F116 (Ch1 R120 (475') (379'-476'), Hinge 1-15 (477'-491'), Ch2 L1.3>A (495'), L1.2>A (496') (492'-601'), Ch3 E12 (617'), M14 (619'), T22>S (627'), L24>A (629'), Y86>V (686'), H115>R (696'), Y116>F (697') (602'-706'), Chs K2>Del (707')) (379'-707')]]; Dimer (485-487':488-490')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Cell Line Cho-K1, Glycoform Alfa
Neuroendocrine Carcinoma
Boehringer IngelheimP2CCC (53)
Niraparib
Neuroendocrine Carcinoma
M.D. Anderson Cancer CenterP2CCC (53)
Surufatinib
Neuroendocrine Carcinoma
Tianjin Medical University Cancer Institute and HospitalP2CCC (53)
Berzosertib
Neuroendocrine Carcinoma
National Cancer Institute (NCI)P1/2CCC (52)
Pyruvate
Neuroendocrine Carcinoma
Rigshospitalet, DenmarkP2CCC (49)
Durvalumab
Neuroendocrine Carcinoma
IDEAYA BiosciencesP1/2CCC (48)
ide161
Neuroendocrine Carcinoma
IDEAYA BiosciencesP1/2CCC (48)
ide849
Neuroendocrine Carcinoma
IDEAYA BiosciencesP1/2CCC (48)
Immunoglobulin H-Gamma1_L-Kappa, Anti-[Homo Sapiens Cd47 (Cd47 Molecule, Integrin Associated Protein, Iap, Mer6, Oa3) And Anti-[Homo Sapiens Dll3 (Delta-Like Ligand 3, Delta Like Canonical Notch Ligand 3)], Bispecific;
Neuroendocrine Carcinoma
Phanes TherapeuticsP1/2CCC (48)
Mrt-2359
Neuroendocrine Carcinoma
Monte Rosa Therapeutics, IncP1/2CCC (48)
Gocatamig
Neuroendocrine Carcinoma
Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)P1/2CC (45)
Ifinatamab Deruxtecan
Neuroendocrine Carcinoma
Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)P1/2CC (45)
Vsv-Ifnβ-Nis
Neuroendocrine Carcinoma
Vyriad, Inc.P1/2CC (45)
zg005
Neuroendocrine Carcinoma
Suzhou Zelgen Biopharmaceuticals Co.,LtdP1/2CC (45)
zg006
Neuroendocrine Carcinoma
Suzhou Zelgen Biopharmaceuticals Co.,LtdP1/2CC (45)
ro7616789
Neuroendocrine Carcinoma
Hoffmann-La RocheP1CC (44)
Tocilizumab
Neuroendocrine Carcinoma
Hoffmann-La RocheP1CC (44)
[212pb]vmt-alpha-net
Neuroendocrine Carcinoma
National Cancer Institute (NCI)P1CC (43)
Bl-M14D1
Neuroendocrine Carcinoma
SystImmune Inc.P1CC (43)
Cyclophosphamide
Neuroendocrine Carcinoma
National Cancer Institute (NCI)P1CC (43)
Egfr/B7H3 Car-T
Neuroendocrine Carcinoma
National Cancer Institute (NCI)P1CC (43)
Elimusertib
Neuroendocrine Carcinoma
National Cancer Institute (NCI)P1CC (43)
exs74539
Neuroendocrine Carcinoma
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.P1CC (43)
Fludarabine
Neuroendocrine Carcinoma
National Cancer Institute (NCI)P1CC (43)
Fluorthanatrace F-18
Neuroendocrine Carcinoma
Abramson Cancer Center at Penn MedicineP1CC (43)
177lu-dtpa-sc16.56
Neuroendocrine Carcinoma
Memorial Sloan Kettering Cancer CenterP1CC (41)
Cid-078 Monotherapy
Neuroendocrine Carcinoma
Circle PharmaP1CC (41)
mt-4561
Neuroendocrine Carcinoma
Tanabe Pharma America, Inc.P1/2NR ()